Aethlon Medical announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier therapy that is being conducted at DaVita Med Center Dialysis in Houston. The study, which will enroll individuals infected with Hepatitis C virus, who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration. Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease patients who are infected with the Hepatitis C virus to demonstrate the safety of Hemopurifier therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications. The feasibility study will also contribute safety data to advance Hemopurifier therapy as a broad-spectrum countermeasure against category A bioterror and pandemic threats that are not addressed with proven drug or vaccine therapies. Read the full press release available here: bit.ly/1yDvjPj
Posted on: Thu, 11 Dec 2014 14:58:30 +0000
Trending Topics
Recently Viewed Topics
© 2015